All stock lists
First Tracks Biotherapeutics, Inc. (NASDAQ:TRAX)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
43.95-0.10 (-0.23%)
Insider Score
––Not scored
TRAX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
TRAX analyst forecast
TRAX analyst consensus
Moderate Buy9 ratings
Buy 9 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
TRAX 12-month price target
$70.00+59.7% upsideaverage of 1 firm
$70.00High
$70.00Low
Best analysts covering TRAX
No firm covering TRAX has enough calls with a finished 1Y holding period to rank yet.
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
TRAX analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-10-16 |
| — | Evercore ISI Group | Outperform | — | — | Reiterated | 2026-10-13 |
| Wells Fargo | Overweight | $70.00 | +105.6% | Reiterated | 2026-10-13 | |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-10-13 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-09-03 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-08-13 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-08-13 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-08-13 |
| — | Piper Sandler | Overweight | — | — | Reiterated | 2026-08-13 |
| — | UBS | Buy | — | — | Reiterated | 2026-08-10 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-07-28 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-07-28 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-21 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-10 |
| — | HC Wainwright & Co. | Buy | — | — | Reiterated | 2026-07-08 |
TRAX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-05-14 | -0.98 | -1.45 | $22.3M | $0 |
| 2026-08-12 | -0.80 | -0.95 | $75.0M | $0 |
| 2026-11-11 | -0.92 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.